FindTrial
Sign In

Early Palliative Care for patients with Hematological Neoplasms

Prognostic and Epidemiological Evaluation of Palliative Care in Hematological Diseases

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-25zhwfj
Enrollment
Unknown
Registered
2023-09-05
Start date
2022-08-16
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Neoplasms

Interventions

Study 1, Multiple myeloma, randomization into two groups (1) Conventional treatment plus Palliative care at diagnosis versus (2) Conventional treatment plus Palliative care only if the patients' hemat
Z51.5

Sponsors

Hemocentro de Campinas
Lead Sponsor
Universidade Estadual de Campinas
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Multiple myeloma, newly diagnosed; previously untreated. Acute myeloid leukemia, newly diagnosed; ineligible to intensive chemotherapy; 60 years-old or higher

Exclusion criteria

Exclusion criteria: Cognitive impairment compromising responses to clinical questionaires

Design outcomes

Primary

MeasureTime frame
Evaluation of Survival outcomes. The study supposes that early palliative care intervention might result in greater patient survival;Evaluation of Quality of life according to The Palliative Performance Scale, The Edmonton Symptom Assessment System and the functional assessment of cancer therapy. The study supposes that early palliative care intervention might result in favorable outcomes (better scores)—

Secondary

MeasureTime frame
No secondary outcomes are expected—

Countries

Brazil

Contacts

Public ContactPaula de Melo Campos

Hemocentro de Campinas

pmcampos@unicamp.br+55-019-3521-8665 / +55-019-3521-8644

Outcome results

None listed

Source: REBEC (via WHO ICTRP)